Table 1 Population characteristics at baseline

Gender: women (% n/N)

77 (474/612)

77 (278/359)

77 (196/253)

  ≤ 34

20 (122/602)

16 (57/352)

26 (65/250)^a

 35–49

25 (150/602)

24 (85/352)

6 (65/250)

 50–64

38 (231/602)

41 (146/352)

34 (85/250)

  ≥ 65

16 (99/602)

18 (64/352)

14 (35/250)

Number of years of education (md, q1-q3, N)

12, 10–13, 594

12, 9–14, 355

12, 10–13, 239

Number of smoked cigarettes/day (data journal) (md, q1-q3, N)

10, 0–20, 505

8, 0–15, 297

11, 3–20, 208^a

No smoking in the week before baseline (% n/N)

28 (171/609)

34 (121/359)

20 (50/250)^a

Number of years smoked before baseline (md, q1-q3, N)

32, 17–40, 575

35, 20–43, 344

30, 15–40, 231^a

Snus use the week before baseline (% n/N)

7 (38/552)

6 (18/318)

9 (20/234)

Exposed to passive smoking (baseline) (% n/N)

26 (147/573)

22 (74/336)

31 (73/237) ^a

Drug use (NRT, Zyban®, Champix®) the week before baseline (% n/N)

52 (308/592)

57 (198/349)

45 (110/243) ^a

Other support at baseline (% n/N)

71 (428/600)

73 (254/349)

69 (174/251)

Likelihood of being smoke-free in 1 year (baseline, 1–10) (md, q1-q3, N)

8, 7–10, 590

9, 7–10, 347

8, 7–10, 243

Handle stress and depression successfully without smoking (baseline, 1–10) (md, q1-q3, N)

7, 4–9, 590

7, 4–9, 346

6, 4–8, 244 ^a

Will use pharmaceuticals if necessary (baseline,1–10) (md, q1-q3, N)

10, 5–10, 592

10, 5–10, 348

9, 5–10, 244